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Donor Leukocyte Infusions Are Effective in Relapsed Multiple Myeloma
After Allogeneic Bone Marrow Transplantation
By H.M . Lokhorst, A. Schattenberg, J J . Cornelissen, L.L.M. Thomas, and L.F. Verdonck
Donor leukocyte infusions (DLI) can induce sustained remis­
sions in patients with acute and chronic myeloid leukemia
(GVHD), which occurred in 66% and 56% of all patients and 
in 87% and 85% of the responders, respectively. Two re-
who relapse after allogeneic bone marrow transplantation sponding patients developed fatal BM aplasia. The only
(allo-BMT). Also, in multiple myeloma (MM), incidental re­ prognostic factors for response were a T-cell dose greater
ports have indicated the existence of a graft-versus-my- than 1 x 108/kg and the occurrence of GVHD. Seven of nine 
eloma effect (GVM) induced by allo-reactive T cells. We per- patients developing acute GVHD responded, as compared 
formed a retrospective study in a larger group of MM with only 1 response in the 4 patients without GVHD and 6
patients to characterize better the effect, prognostic factors. of 7 patients with chronic GVHD responded, whereas no
and toxicity of this new treatment modality. Thirteen pa- response was observed in the 5 patients without chronic
tients with relapsed MM after allo-BMT were studied. Pa- G VHD. DLI are effective in a high percentage of patients with
tients received a total of 29 DLI with T-cell doses ranging relapsed MM after allo-BMT, although it is associated with
from 1 x 106/kg to 33 x 107/kg. Repetitive courses, some- a high treatment-related toxicity. The dose of T cells used
times with escalated cell doses, were undertaken in case of may be important in determining the GVM effect, with the
no response to or relapse after DLI. Eight of 13 patients highest probability of response after infusion of more than
responded: 4 patients achieved a partial remission and 4 1 x 108 T cells. Because the optimal individual dose may
patients achieved a complete remission. Dose escalation 
was effective in 3 patients. The time to response was median 
6 weeks (range, 4 to 10 weeks). Major toxicities were sec­
ondary to acute and chronic graft-versus-host disease
vary, patient-adapted therapy consisting of repeated infu­
sions with escalating dose of donor leukocytes until maxi­
mum response is achieved may therefore be preferable. 
1997 by The American Society of Hematology.
NTENSIVE TREATMENT, including high-dose chemo­
therapy/radiotherapy with either allogeneic or autolo­
gous stem cell transplantation has been widely used in multi­
ple myeloma (MM) patients during the last decade and may 
improve long-term survival and induce long periods of un­
maintained disease control.1'6 It is still controversial whether 
allogeneic bone marrow transplantation (allo-BMT) should 
be offered to younger patients with an HLA-identical sibling. 
In a recent retrospective analysis of the European Group for 
Blood and Marrow Transplantation (EBMT), no advantage 
could be shown for allo-BMT in general as compared with 
autologous stem cell transplantation (ASCT).7 A high treat­
ment-related mortality (TRM) in the first year after allo- 
BMT was the major problem in MM. However, the fact that 
in patients alive at 1 year after transplantation the disease- 
free survival was significantly longer after allo-BMT as com­
pared with ASCT suggests a favorable graft-versus-myeloma
remission (CR) after DLI, which has persisted in I patient 
for already more than 3 years.9 Both patients who received
3.3 X 10 and 1.2 X 10 T cells/kg, respectively, developed 
moderate graft-versus-host disease (GVHD) that was respon­
sive to mild immunosuppressive therapy.9
This study, which summarizes the results of DLI in a 
larger group of patients from BMT centers in the Nether­
lands, shows that this form of adoptive immunotherapy in­
duces response in the majority of relapsed MM patients. This 
observation adds further proof for the existence and benefits 
of a GVM effect.
MATERIALS AND METHODS
Patient characteristics. Sixty-one patients with MM received an 
allo-BMT from I-ILA-identical siblings from 1987 until now at four 
BM centers in the Netherlands. Patients who were refractory to or 
relapsed after allo-BMT were candidates for DLI. Patients were
(GVM) effect. Recently, the existence of GVM was shown ineligible if they had a performance status 4 (World Health Organi/.a- 
more directly by remissions occurring after donor leukocyte tion), active GVHD, severe infection, and abnormal liver or renal
infusions (DLI) in patients with relapse MM after alio function. A total of 13 patients (median age at the time of first D U ,
BMT.8,9 We described 2 patients who achieved complete ^8 years; range, 38 to 56 years) with relapsed MM after allo-BMT
were included. Two patients (patients no. 1 and 5) have been de­
scribed before.1' Their Ibllow-up has been updated. Patient character­
istics including pretransplant therapies, BMT procedures, and outFrom the Department of Haematology, University
Utrecht, Utrecht, The Netherlands; the Department of Haematology, come are summarized in Table 1. Except for patient no. 9, who
University Hospital, Nijmegen, The Netherlands; the Department of received a transplant from a haploidentieal brother, all patients re-
Haematology, Dr. Daniel den Hoed Clinic, Rotterdam, The Nether- ceived BMT from HLA-identical siblings. All patients received a
lands; and the Department of Haematology, Academic Medical Cen- partial T-cell-depleted graft, generally containing I X Hf ’I' cells/
ter, Amsterdam, The Netherlands.
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kg recipients’ weight (Table 1). All patients received prophylactic
immunosuppression consisting of cyclosporin A. Immunosuppres-
Address reprint requests to H.M. Lokhorst, MD, PhD, University sive treatment was stopped 3 months after BMT in case GVMD
Hospital Utrecht, Department of Haematology (G03.647), PO Box a grade 2 was absent. In 12 patients, immunosuppression was
85.500/Heidelberglaan 100, 3508 GA Utrecht/3584 CX Utrecht, The stopped at least 6 months before DLI. In patient no. 8, cyclosporin
Netherlands. was stopped 2 months after allo-BMT and 1 month before DLI in
The publication costs of this article were defrayed in part by page the absence of GVHD.
charge payment. This article must therefore be hereby marked Immunotherapy with DLL Donor leukocytes from the original
“advertisement” in accordance with 18 U.S.C. section 1734 solely to marrow donor were obtained by leukapheresis in 1 to 5 sessions.
indicate this fact. Cells were infused without further manipulation. Calculation of the
i
© 1997 by The American Society of Hematology.
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number of T cells infused was performed by FACSean analysis of 
buffy coat cells using CD3-speeific monoclonal antibodies. A total
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Lines of Previous 
Chemotherapy 
(n) Conditioning*










1 49/F 2A Resistant 2 a 04/03/92 F + 1 0/nil PR 15
2 45/M 2A Resistant 3 a 09/04/91 M + 1.1 1/limited NR 15
3 47/M 1A PR 1 d 07/20/94 M +0.6 0/nil CR 8
4 37/M 1A Resistant 1 a 06/18/87 M + 1 0/nil PR 87
5 53/M 3A PR 2 a 08/01/92 M + 1 2/nil PR 25
6 37/F 2A PR 1 a 05/09/90 F +0.8 1/limited CR 60
7 50/M 3A Resistant 1 b 12/02/92 M +0.9 0/nil NR 25
47/M 3A Resistant 2 c 06/28/95 F +1 0/nil CR 5
91* 43/F 2A PR 1 a 05/18/88 M +1.3 1/limited CR 63
10 55/M 3A Resistant 1 a 07/21/95 F + 1 1/nil PR 9
11 49/F 2A PR 2 a 08/27/93 M +1 1/nil PR 27
12 44/M 3A Resistant 2 a 06/16/95 M 11 2/limited PR 11
13 40/M 3A PR 2 a 01/11/96 M + 1 2/llmited PR 8
Abbreviation: TCD, T-coll doso x l0 6/kg.
* a, 120 mg/m2 cyclophosphamide i TBI; b, ifosfamide i malphalan; c, busulfan 
t  Hapioidantical sibling BMT, all other patients genotypically identical sibling.
i cyclophosphamide; d, idarubicine i- cyclofosfamido + TBI.
of 29 DLI procedures were performed in 13 patients. In patients 
who did not respond or relapsed after DLI, repetitive courses of 
DLI, sometimes with escalated T-cell doses, were undertaken. The 
cumulative number of T cells infused ranged from 1 X  10(,/kg to 33 
X 107/kg. T-cell numbers per DLI course are listed in Table 2.
Definition o f  response and relapse. A partial remission (PR) was 
defined as at least 50% or more tumor reduction as measured by 
decrease in myeloma proteins in serum and/or urine measured at 
least twice and lasting for at least 2 months. In responding patients, 
BM evaluation had to be in agreement with myeloma protein mea­
surement and had to be accompanied by improvement of clinical 
symptoms as well. A CR was defined as the complete disappearance
of myeloma proteins and absence of bone marrow monoclonal
sma cells. Relapse was defined as the doubling of myeloma 
proteins measured at least twice and in patients with CR as the 
reappearance and subsequent increase of myeloma proteins.
Definition of GVHD. The clinical manifestations of acute GVHD 
were graded I to IV according to the criteria described by Thomas 
et al." Chronic GVHD was classified as limited or extensive as 
described by Shulman et al.12 If GVHD occurred =s3 months after 
BMT or ss3 months after donor leukocyte infusions, it was defined 
as acute. If the patient had GVHD beyond 3 months, it was defined 
as chronic.
Analysis of chimerism. Analysis of chimerism of peripheral
Table 2. Details of T-Cell Doses Infused and Response to DLI
Patient
No.
Time From Relapse 
or Progression to 
DU (wk)






















(mo) Causes of Death
1 4 33 H B «» CR 6 38 + 3/extensive Donor 38+
2 16 16 WtBiW NR NA MWWH 0/nil ND 28 Progressive disease
3 32 7 NR NA IVtiZti'« 1/nil Donor 17 +
4 24 NR NA 0/nil Donor
8 9 NR NA 0/nil Donor
8 20 NR NA 0/nil Donor
4 13 5 NR NA Mr-Liii+4 0/nil ND 26 +
10 12 NR NA 2/nil ND
25 22 PR 10 5* 3/limited
14 44 PR {NAÎ 4 3 i 0/nil Donor
5 12 12 .«tkMÏ-- CR 7 14 2/Hmitöd Donor 25 +
24 1 82 NR NA 0/nil Donor
10 9 NE NA * J NE
6 10 9 NR NA rvV.**; 0/nil Donor 20 +
8 9 NR NA jk .‘t*. r.i 0/nil Donor
10 32 NR NA M I;:v 0/nil Donor
20 12 NR NA !? Vr 0/nil Donor
7 68 7 fr**** CR 8 18) 3/extensive Mixed 18+
8 1 8 PR 5 2" 3/NE Mixed 3 Septicemia
9 112 3 NR NA JO 1/limited Donor 9 Septicemia
6 18 PR 6 3® 1/limited
10 11 5 PR 5 2 + 0/nil Donor 7 I
+ 0.3 x  10° CD34/kg
15 7 CR 5 7 + 3/limited
+0,6 X 10° CD34/kg
11 28 5 »-«j *«» NR NA 0/nil Donor 6 1
10 10 NR NA 0/nil
12 12 0.1 ■rffc/, PR 6 41 0/nil Donor 8+
1 14 NE NA 0/nil
13 34 3 NR NA 2/nil ND B+
5 16 NE NA NE
a a m *
Abbreviations: NE, not evaluable; NA, not applicable; ND, not done; S, aensored; NR, no response; CR, complete response.
* Relapse was treated with VAD (3x) and intermediate-dose melphalan {70 mg/m* IV).
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blood T cells and non-T cells was performed by polymerase chain 
reaction of tandem-repeat sequences of hypervariable regions of 
human DNA as described before.11 In addition, in sex-mismatched 
transplants, chimerism was evaluated by fluorescence in-situ hybrid­
ization (FISH) using X-chromosome- and Y-chromosome-specific 
probes. These probes were used in conjunction with T-cell-specific 
monoclonal antibodies, eg, CD5 and CD3, coupled to alkaline phos- 
phatase-antialkaline phosphatase (APAAP) and cells were analyzed 
on cytospin slides as described before.14
RESULTS
Response. Eight of 13 (62%) patients responded. Four 
patients achieved a PR and 4 patients a CR. Six patients 
responded after the first dose of leukocytes containing be­
tween I X 10fi and 33 X 107 T cells/kg. Dose escalation did 
induce a partial remission in 2 initial nonresponding patients 
and a CR in 1 partially responding patient. Dose escalation 
had no effect in 3 nonresponding patients. It is still too early 
to evaluate the effect of dose escalations in 2 other patients 
(patients no. 12 and 13). The median time to response was 
6 weeks (range, 4 to 10 weeks). Two patients relapsed bio­
chemically and overt clinically 5 and 14 months after DLI, 
respectively. The first patient (no. 4) then received 3 courses 
of VAD chemotherapy (vincristine, adriamycin, dexametha- 
sone)15 followed by intermediate-dose melphalan at 70 mg/ 
nr intravenously (IDM)4 followed by infusion of unmanipu­
lated peripheral blood stem cells (PBSC; 4.6 X 106 CD34V 
kg) containing 14 X 107 T cells/kg. The patient went into 
PR, but is not assessable for response to the last DLI due to 
the prior chemotherapy. The other patient (no. 5) received
1 X 107 donor T cells/kg without response, followed 9 weeks 
later by 1 X I0B donor T cells/kg, still without response 
evaluated 4 weeks after the last DLI. The median response 
duration was 5 months (range, 2+ to 38+ months). Details 
of T-cell doses administered, responses in correlation with 
toxicity profiles, and durations of survival are shown in Table
2
Follow-up o f  nonresponding patients. Patient no. 2 re­
ceived no further treatment and died from progressive dis­
ease 28 months after DLI.
Two patients were treated with chemotherapy. Patient no.
3, who had progressive symptomatic disease after the fourth 
DLI, showed a good clinical and partial biochemical re­
sponse to 3 courses of cyclophosphamide, adriamycin, and 
prednisone combination lasting 6 months. It is too early to 
evaluate the response to the current treatment with conven­
tionally dosed melphalan and prednisone. Patient no. 6, who 
had progressive symptomatic disease during and after DLI, 
was treated with melphalan and prednisone starting 8 months 
after the last DLI. The effect of chemotherapy is not yet 
evaluable. Patient no. 11 was rapidly progressive after the 
last DLI and has received palliative radiotherapy on the tho­
racic spine and left shoulder. Durations of survival are listed 
in Table 2.
Table 3. Correlation Between T-Cell Dose, GVM, and GVHD
T-Cell Dose/kg








<1 X 107 1 1 0 0
1 X 107 to  s 5  X 107 7 1 2 1
5 X 107 to  =s1 X  10a 11 3 4 2
>1  X 10a 6 4 4 4
GVHD grade 1 and limited chronic GVHD. BM aplasia did 
not occur in the other patients. Three patients developed 
acute GVHD grade I, I patient developed grade II, 5 patients 
developed grade III, and 6 patients developed chronic GVHD 
(4 limited and 2 extensive).
Factors correlating with response to DLL Seven of the 
9 patients with acute GVHD and 1 of the 4 patients without 
acute GVHD responded, suggesting a correlation of GVHD 
with response (P = .12; Fisher’s exact test, two-sided). This 
correlation was statistically significant in the patients with 
chronic GVHD: 6 of 7 patients developing chronic GVHD 
responded, whereas none of the 5 patients without chronic 
GVHD showed a response (P = .015; Fisher’s exact test, 
two-sided).
Response was induced after 4 of 6 T-cell doses with more 
than 1.0 X 108/kg, whereas it occurred in only 4 of 21 T- 
cell doses <1.0 X 108/kg (P = .02; Fisher’s exact test, two- 
sided). One of the 2 nonresponding patients who received 
more than 1.2 X 108 T cells/kg did not develop GVHD. 
The relationship between T-cell dose, GVM, and GVHD is 
shown in Table 3.
No definite conclusions could be drawn from the analysis 
of T-cell chimerism in relation to response to DLI. Two 
(responding) patients were mixed T-cell chimeras before 
DLI, whereas 9 other patients (3 CR, 3 PR, and 3 no re­
sponses [NR]) were complete donor T-cell chimeras.
Of the 8 responding patients, 4 (50%) had no GVHD with 
initial BMT, and in 4 of 8 responding patients, the time 
interval between BMT and DLI was less than 2 years.
DISCUSSION
The antileukemic effect of GVHD and DLI is well docu­
mented in both acute leukemia and chronic myeloid leuke­
mia (CML).lf’"28 Also, in myeloma, incidental reports of DLI 
in small numbers of patients have indicated the existence of 
a GVM effect:8,l) Our study in a larger group of patients 
confirms the potency of donor leukocytes to induce re­
sponses in relapsed MM after allo-BMT. Sixty-two percent 
(8 of 13) of our patients responded, including 4 with CR 
(30%). However, the ultimate response rate was 46%, be­
cause 2 responding patients died treatment-related early 
deaths due to BM aplasia. Five responding patients received 
systemic prednisone for treatment of GVHD. However, the 
Toxicity. Two patients developed BM aplasia (patients influence of corticosteroids on response was unlikely, be- 
no. 8 and 9) and died of septicemia. In 1 patient (no. 8), cause 4 of these patients had received high-dose prednisone 
BM aplasia was associated with acute GVHD grade 3. The before without a response. Moreover, CR (in 4 patients) 
other patient (no. 9) developed severe thrombopenia (<30 induced by prednisone alone is improbable. From the 2 pa- 
X 1OTL) 6 weeks and severe neutropenia 8 weeks (<1 X tients with a PR receiving prednisone, in 1 patient (the pa- 
I09/L) after DLI. In this patient, DLI was followed by acute dent with CR after dose escalation) myeloma protein de-
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of patients may therefore be partially due to the fact that the
Fig 1. Durable GVM effect as shown by response of serum M 
protein to infusion of donor T cells in a patient with relapsed my 
eloma after allogeneic BMT. MP, melphalan and prednisone chemo 
therapy.
initial BMT was performed with a T-cell 
containing 105/kg T cells with minimal or no GVHD post­
transplantation. Although the presence or absence of GVHD 
at initial BMT did not relate with response to DLI in our 
series, it is possible that the outcome for non-T-cell-de- 
pleted grafts with more initial severe acute and for chronic 
GVHD may be less successful. In addition, responses may 
have occurred in some patients who would not have relapsed 
if they had received unmodified grafts. This may be shown 
by the fact that the only lasting CRs are present in 3 patients 
with no or very mild GVHD at initial BMT and grade III 
acute GVHD plus chronic GVHD after DLI.
A T-cell dose-response effect of DLI had already been 
shown in leukemia, especially in CML.,8,I<) However, T-cell 
doses required to induce responses in MM may be higher
than in CML. Patients with CML may respond to doses as
6low as 1 X 10 /kg. Although T-cell doses as low as 1 X
clined significantly before the onset and treatment of GVHD. lOVkg may induce GVM (patient no. 12 and the patient 
The other patient was progressive after CHOP chemother- described by Tricot et al8), our data indicate that 5 X 107/ 
apy, whereas a response was measurable at the onset of kg T cells may be preferred as the starting dose. In case of
GVHD. CRs may be durable, because 1 patient is still free 
of disease (no signs of myeloma in blood and/or urine as 
determined by immunofixation and BM as determined by 
immunophenotyping of plasma cells) 3 years after DLI (Fig
no response within 10 weeks, the infusion can be repeated 
with a higher number of donor lymphocytes individually 
adapted on preceding GVHD.
The major toxicides were secondary to acute and chronic
1). Two other patients are still in CR, with a follow-up of GVHD, which occurred in 66% and 56% of all patients and
18 and 7 months, respectively, whereas 1 patient in CR 
relapsed after 14 months. However, longer times of observa­
tion in more patients will be necessary to determine more 
exactly the overall response and duration after DLI in MM. 
The median time to document a response was 6 weeks 
(range, 4 to 10 weeks), which is comparable to patients with 
acute leukemia and CM L.I6,|,>'21
The number of donor leukocytes infused may be important 
in mediating a GVM effect. A T-cell dose of more than 1 
X 108 cells/kg induced a response in 4 of 6 patients (67%), 
compared with only 4 responses after 21 DLI containing =sl 
X 10K T cells/kg. The T-cell dose/response relation was quite
evident in 3 patients who 4Cifter dose escalation,
although it cannot be excluded completely that repeated infu­
sion with the lower dose would have provided the same 
results. Also, a late response to the previous lower dose
so
seemed unlikely, because in 2 previous NR pati 
from the prior infusion was 18 and 22 weeks, respectively 
(patients no. 4 and 9), whereas the third patient (no. 11 ) was 
progressive after initial PR to the 
Apart from the kind of malignancy, pre-DLI cluiracteris 
tics have been described that may predict response, including 
GVHD after initial BMT, time interval between BMT and 
DLI, and the occurrence of GVHD post-DLL213 In our pa­
tients, only the occurrence of GVHD and T-cell dose of 
greater than 1 X lOVkg were correlated with response. Seven 
of 8 responding patients developed acute GVHD and 6 of tionhsip between response and GVHD suggests that GVM
in 87% and 85% of the responders, respectively. The high 
incidence of GVHD in the responders may be related to the 
high number of donor T cells that were used to achieve 
remission. BM aplasia developed in only 2 responding pa­
tients, but was fatal in both patients. Marrow aplasia in up 
to 50% of patients receiving DLI for relapsed CML and 
acute leukemia has been reported.15,16 Kolb et al16 showed 
that DLI in CR of acute leukemia or in cytogenetic relapse 
of CML are less prone to severe myelosuppression. It was 
recently shown that persisting residual donor hematopoiesis 
in relapsed patients protects them from DLI-induced BM 
aplasia.,0 In our group of patients, only 2 were mixed T-cell 
chimeras, but both still had residual donor hematopoiesis at 
the time of DLL as indicated by analysis of peripheral blood 
non-T cells. GVHD grade III probably contributed to the 
fatal aplasia in patient no 8. In the other patients, complete 
donor T-cell chimerism was likely to be associated with 
residual normal donor hematopoiesis. This further indicates 
that donor hematopoiesis usually persists in relapsed MM
allo-BMT and that the incidence of DLI-induced my- 
ssion may therefore be low as compared with acute 
ia and CML.
The recent introduction of techniques to abrogate exces­
sive GVHD by using donor T lymphocytes transduced with 
the suicide gene viral thymidine kinase (TK) may be helpful
2‘UI However, the close rela-
7 responders assessable for evaluation developed chronic 
GVHD. All 5 patients with GVHD gn  
compared with only 1
3 re: as
in 4 patients without
GVHD. It is likely that the association 
cell dose and response is due to a close relationship between 
GVHD and GVM. The high success rate of DLI in our group
is mediated by alloreactive T cells directed against minor
present on both normal and my- 
cells. Elimination of the TK-transduced T cells by in 
vivo administration of ganciclovir might abrogate the GVM
V i * * *
are :e ur
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warranted. Infusion of purified allogeneic immune cells or 
selective elimination of subsets of TK-transduced donor T 
cells may elucidate whether GVM is mediated by a specific 
effector population.
In conclusion, donor leukocyte infusions can induce re­
missions in the majority of patients with relapsed MM after 
allo-BMT. The dose of donor leukocytes used may be im­
portant for the achievement of GVM. Doses of more than 1 
X 108 donor T cells gave the highest probability of response, 
although the optimal individual dose may vary. In MM, 
individually adapted therapy consisting of repeated infusions 
with escalating doses of donor leukocytes until maximal 
response is achieved may therefore be preferable. Efforts, 
including infusion of subsets of T cells,33 combination of 
DLI with cytokines such as interleukin-2, 'y,M and selective 
in vivo elimination of TK-transduced donor effector cells
may reduce the toxicity of GVHD while preserving the GVM 
effect of DLL
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